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s warranted. Active infection control program in resource-limited
ettings for carbapenem resistant Gram-negative pathogens may
nclude modiﬁed active surveillance, contact isolation, cohorting
atients with carbapenem resistant Gram-negative pathogens, 5
oment hand hygiene, environmental cleaning, as well as moni-
oring healthcare workers and providing prompt feedback. These
trategies must be modiﬁed to ﬁt the local setting, organizational
ulture, and infrastructure. Intensiﬁed efforts in infection control
rograms and antibiotic stewardship serve as key components
or long-term success. Given the limited information of infec-
ion control for carbapenem resistant Gram-negative pathogens
n resource-limited setting, additional well-designed studies are
eeded to explore various aspects of outcomes of antimicrobial
tewardship and infection control in resource-limited settings.
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olio eradication – Incorporating IPV more broadly
. Vidor
Sanoﬁ Pasteur, Lyons, France
While the oral poliovirus vaccine (OPV) has been an important
ool in moving towards global eradication of poliomyelitis, its con-
inued use is associated with the ongoing emergence of circulating
accine-derived polioviruses (cVDPVs) and the sporadic occur-
ence of vaccine-associated paralytic poliomyelitis (VAPP) cases.
dditionally, sub-optimal andgeographically inconsistent serocon-
ersion rates following OPV administration further confound the
oal of global eradication.
The inactivated poliovirus vaccine (IPV), however, is not asso-
iated with cVDPVs or VAPP, and results in more consistent
ost-vaccination seroconversion rates. With these advantages in
ind, it is clear that IPV can play a vital role in global poliomyeli-
is eradication, but IPV is less straightforward to administer and is
laimed to be more expensive to deploy than OPV. Mixed and com-
ined OPV/IPV schedules can be used to maximize the beneﬁts of
oth vaccines.
TheWHOconsiders that IPVcouldhavean important role toplay
n low- to middle-income countries, where polio is particularly dif-
cult to eradicatedue to the continueduseofOPV. There arevarious
ossibilities, each with its own pros and cons and variable feasibil-
ty, to promote a broader incorporation of IPV in such countries,
ncluding; fractional doses administered intradermally; develop-
ent of new adjuvants for IPV antigens; an intramuscular schedule
ith a reduced number of doses; or the use of whole-cell pertussis
wP), rather than the more expensive acellular pertussis antigens,
n combination with IPV (eg, hexavalent wP-IPV-containing vac-
ines). In addition, the use of standalone IPV following previous
PV doses could also reduce the immunity gap that is present in
any pediatric populations.
The WHO currently envisages the cessation of wild-typeoliovirus circulation by 2014 through use of IPV, followed by con-
inued IPV use to assure and maintain global eradication.
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The evolution of pertussis vaccines and vaccination programs
U. Thisyakorn
Chulalongkorn University, Bangkok, Thailand
Pertussis, sometimes called whooping cough, is a highly conta-
gious disease that remains an important cause of death worldwide,
more particularly in developing countries. Its mortality occurs
largely in infants less than 1 year of age, especially among those
who have not completed their primary vaccinations.
Diphtheria and tetanus toxoids combinedwithwhole cellBorde-
tella pertussis (DTwP) vaccines were developed and licensed during
the 1940s, have been widely used for over 60 years, and have been
central to theWHOExpandedProgramon Immunization (EPI) since
its inception in 1974, leading to considerable impact in controlling
pertussis. However, there are still global disparities with regard to
vaccine use and coverage.
Concerns about the reactogenicity of DTwP vaccines led to
reduced immunization coverage and a subsequent increase in dis-
ease incidence in some countries. This prompted the development
of acellular (aP) pertussis vaccines, which have a considerably bet-
ter safety proﬁle.
Currently, DTaP vaccines – sometimes combined with other
antigens – are used in the national immunization programs
in Canada, the United States, various European countries (eg,
Denmark, France, Germany, Ireland, Italy, Spain, Sweden, UK),
Asia (eg, Japan, South Korea), Australia, Costa Rica, Mexico, South
Africa, and Turkey. National surveillance programs and speciﬁc
studies in Europe and North America have demonstrated that the
licensed aP vaccines, regardless of the number of acellular pertus-
sis components contained therein, have substantial effectiveness
in preventing pertussiswhen used comprehensively among infants
and young children.
Thebroaderdeploymentof aPvaccines andchildhoodcombined
vaccines is of considerable public health interest. Experience with
the use of these vaccines will be presented.
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Pentavalent and hexavalent combination vaccines of today and
tomorrow
S. Madhi
National Institute for Communicable Diseases (NICD), Johannesburg,
South AfricaVaccines are cost-effective public health tools for the preven-
tion and control of infectious diseases. However, disparity in access
to health care remains a major hurdle to accessing life-saving
